1. Рекомендации по лечению стабильной ишемической болезни сердца Европейского общества кардиологов 2013. Адаптированный перевод. Рос. кардиол. журн. 2014; 7: 7–79.
2. Sekiya M, Sato M, Funada J, Ohtani T et al. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol 2005; 46 (1): 63–7.
3. Zhu WL, Shan YD, Guo JX et al. Double-blind, multicenter active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China. Circ J 2007; 71 (6): 826–33.
4. The IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359: 1269–75.
5. Horinaka S, Yabe A, Yagi H et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. Circ J 2010; 74 (3): 503–9.
6. Sakata Y, Nakatani D, Shimizu M et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction. J Cardiol 2012; 59 (1): 14–21.
7. Булахова Е.Ю., Кореннова О.Ю., Кондрашева М.Н. и др. Клинические преимущества терапии никорандилом в сравнении с изосорбид-5-мононитратом у больных ИБС. Сердце. 2013; 2 (70): 83–7.